Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 2/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ACACB | O00763 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | ACACA | Q13085 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8038293 | 1.00 | TSPO (0.39) | TSPOPDE5AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL8037926 | 1.00 | TSPO (0.39) | TSPOPDE5AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL8037891 | 0.99 | TSPO (0.40) | TSPOPDE5AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL8037916 | 0.91 | TSPO (0.44) | TSPOPDE5AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL8039708 | 0.89 | PTPN1 (0.40) | ALDH1A1KMT2ATSHRLMNA | |
| SCHEMBL8039546 | 0.89 | PTPN1 (0.40) | ALDH1A1KMT2ATSHRLMNA | |
| SCHEMBL6405116 | 0.89 | PTPN1 (0.40) | ALDH1A1KMT2ATSHRLMNA | |
| SCHEMBL8038304 | 0.89 | PTPN1 (0.40) | ALDH1A1KMT2ATSHRLMNA | |
| SCHEMBL8039689 | 0.88 | PTPN1 (0.38) | KMT2ATSHRACACBPOLBLMNA | |
| SCHEMBL8037976 | 0.87 | MMP13 (0.36) | KDM4EALDH1A1ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050027008-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredient | TEIJIN LIMITED | 2005-02-03 | — | — | US | disclosed |
| US-20030220402-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredients | TEIJIN LIMITED (JP) | 2003-11-27 | — | — | US | disclosed |
| EP-1256341-A1 | CANCER REMEDY COMPRISING ANTHRANILIC ACID DERIVATIVE AS ACTIVE INGREDIENT | TEIJIN LIMITED (JP) | 2002-11-13 | — | — | EP | disclosed |
| EP-0806412-B1 | BENZENE DERIVATIVES | TEIJIN LTD (JP) | 2000-04-05 | — | — | EP | disclosed |
| US-5808144-A | ANTIALLERGENS | TEIJIN LIMITED (JP) | 1998-09-15 | — | — | US | disclosed |
| EP-0806412-A1 | BENZENE DERIVATIVES | TEIJIN LIMITED (JP) | 1997-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220402-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredients | HCCS, BCOR, CBR1 | TSPO 769/4885PDE5A 4850/4885KDM4E 1406/4885 |
| US-20050027008-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredient | CA9, HCCS, CA7 | TSPO 678/4885PDE5A 4579/4885KDM4E 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.